# Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation

> **NCT02985775** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 41 (actual)

## Conditions studied

- CMV Infection

## Interventions

- **BIOLOGICAL:** Donor-derived CMVpp65-specific T cells

## Key facts

- **NCT ID:** NCT02985775
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2018-03
- **Final completion:** 2019-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02985775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02985775, "Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02985775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*